DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Recruiting now · Phase 3
Conditions studied: Endometrial Cancer
In brief
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
Key facts
- Study ID
- NCT06989112
- Run by
- AstraZeneca
- People needed
- 600
- Starts
- 2025-03-27
- Expected to finish
- 2031-02-19
- Last updated by the study team
- 2026-06-23
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Research Site — New York, New York, United States (enrolling)
- Research Site — Columbus, Ohio, United States (enrolling)
- Research Site — Springfield, Missouri, United States (enrolling)
- Research Site — Lebanon, New Hampshire, United States (enrolling)
- Research Site — Winston-Salem, North Carolina, United States (enrolling)
- Research Site — Cincinnati, Ohio, United States (enrolling)
- Research Site — Jackson, Mississippi, United States (enrolling)
- Research Site — Fort Myers, Florida, United States (enrolling)
- Research Site — Miami Beach, Florida, United States (enrolling)
- Research Site — St Louis, Missouri, United States (enrolling)
- Research Site — Charlotte, North Carolina, United States (enrolling)
- Research Site — Tampa, Florida, United States (enrolling)
- Research Site — West Palm Beach, Florida, United States (enrolling)
- Research Site — Augusta, Georgia, United States (enrolling)
- Research Site — Little Rock, Arkansas, United States (enrolling)
- Research Site — Arlington Heights, Illinois, United States (enrolling)
- Research Site — Evanston, Illinois, United States (enrolling)
- Research Site — Shreveport, Louisiana, United States (enrolling)
- Research Site — Baltimore, Maryland, United States (enrolling)
- Research Site — Boston, Massachusetts, United States (enrolling)
- Research Site — La Jolla, California, United States (enrolling)
- Research Site — Ann Arbor, Michigan, United States (enrolling)
- Research Site — St. Petersburg, Florida, United States (enrolling)
- Research Site — Minneapolis, Minnesota, United States (enrolling)
- Research Site — Eugene, Oregon, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.